BioPharmSignal logoBioPharmSignal

Biotech News

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

PLUS THERAPEUTICS, Inc. (PSTV)PLUS THERAPEUTICS, Inc.Company update

Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.

Related news

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

STROSutro Biopharma2026-09-29 12:00 EST

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

LEGNLegend Biotech Corporation2026-09-15 12:00 EST

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

ANGOAngioDynamics2026-10-08 10:00 EST

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

ELVNEnliven Therapeutics2026-10-06 20:05 EST

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

View all latest news

PLUS THERAPEUTICS, Inc.

PLUS Therapeutics is an oncology company focused on radiotherapeutics and targeted treatment delivery for cancer. Its story is built around the use of radiation-based approaches to address hard-to-treat tumors.

Recent company news

PSTVPLUS THERAPEUTICS, Inc.2026-06-04 11:30 EST

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

PSTVPLUS THERAPEUTICS, Inc.2026-05-26 11:30 EST

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

PSTVPLUS THERAPEUTICS, Inc.2026-05-19 11:30 EST

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

PSTVPLUS THERAPEUTICS, Inc.2026-05-15 20:05 EST

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

PSTVPLUS THERAPEUTICS, Inc.2026-05-08 11:30 EST

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Stock data

Close
3.87 USD
Market cap
37.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States